CEDO
Cedo , one of Europe’s largest manufacturers of household waste bags made with recycled plastics, has made its first major leap towards becoming a climate neutral business, powering its UK factory in Telford and offices in Paris and Mönchengladbach with 100 per cent renewable energy. Its UK business, based in Shropshire, has also achieved its target of sending zero manufacturing waste to landfill.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005178/en/
More than 23 per cent of Cedo’s global operations now use 100 per cent renewable energy, with suppliers including green energy provider Total and PGE S.A in Poland. Cedo’s remaining factories in Vietnam, Poland and the Netherlands are also on target to achieve climate neutrality over the next few years.
“Cedo’s aim is to become a climate neutral business worldwide by 2030. By increasing our use of renewable energy year-on-year while focusing our efforts on achieving zero manufacturing waste to landfill, we are making rapid progress towards our goal,” said Rik De Vos, CEO of Cedo. “Our next ambition is to continue to pursue a more circular approach in our stewardship of raw materials, while creating a sustainable business that is no longer reliant on fossil fuel-based virgin polymers.
“In the very near future every Cedo non-food product will be fully recycled and recyclable. We believe that keeping our homes clean, safe and tidy in an environmentally friendly way should be as simple as putting out the bins,” said De Vos.
Established in 1965, Cedo is one of the world’s leading plastics recycling businesses, specialising in the recycling of post-consumer household packaging waste such as plastic packaging and clingfilm. Every year, the business uses more than 80,000 tons of recycled plastic to make over 4 billion refuse sacks and bin liners from factories based in Poland, the Netherlands, Vietnam and the UK, operating one of the largest flexible plastic film recycling centres in Europe.
Cedo products from bin liners to food wrap and latex gloves can be found in supermarkets and retailers in 34 countries. In the UK, 93% of the plastic used by Cedo to manufacture non-food products is from recycled sources.
As we approach Earth Overshoot Day on 29 July, Cedo is one quarter of the way to achieving its 100 per cent renewable energy goal, which will see it becoming a climate neutral business by 2030.
- Ends –
About Cedo
Established in 1965, Cedo is one of Europe's largest and most sustainable suppliers of refuse sacks made from recycled plastics, as well as other consumer household products designed to protect and store food. For more than thirty years it has led the development of recycling mixed plastic film recovered from households to give more plastic a second life, creating 100% recycled and 100% recyclable products designed to keep European households, workplaces and leisure spaces clean, healthy and safe.
As founding signatories to both the Ellen MacArthur Foundation’s New Plastics Economy Global Commitments and the European Plastics Pact, Cedo is working with partners including NGO The Plastic Bank to create new solutions and interventions to address the challenges of building a new plastics economy.
For two years, Cedo has been recognised by the Sunday Times top track 250 (fast growing medium sized privately owned business). By 2030 the business will be climate neutral across its global operations.
For more information please visit cedo.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005178/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
